TY - JOUR T1 - CARESS: The Canadian registry of palivizumab (2005-2010) JF - European Respiratory Journal JO - Eur Respir J VL - 38 IS - Suppl 55 SP - p1148 AU - Ian Mitchell AU - Bosco Paes AU - Abby Li AU - Krista Lanctot Y1 - 2011/09/01 UR - http://erj.ersjournals.com/content/38/Suppl_55/p1148.abstract N2 - Objective: To evaluate the current management of children at high-risk of RSV infection who received palivizumab prophylaxis in tertiary care centers and community settings using a Canadian Registry Database.Methods: A prospective, observational, registry of infants who received ≥1 dose of palivizumab during the 2005-2010 RSV seasons across 29 sites. Data on palivizumab utilization and compliance, and outcomes related to a respiratory infection were collected monthly until the full course of palivizumab was completed.Results: 7699 infants were enrolled, with an average age of 5.4±6.0 months. Participants were typically male (56.4%), Caucasians (71.5%), with an average gestational age (GA) of 32.2 (SD 6.0) completed weeks. 5237 (68.0%) infants received palivizumab for prematurity (35 completed weeks GA) only, 766 (9.9%) for congenital heart disease, 646 (8.4%) for chronic lung disease and 1050 (13.6%) for other risk factors (e.g., CNS disorders, airway anomalies and cystic fibrosis). Patients received an average of 3.9 (SD 1.6) injections, with 30,040 doses given overall. 5.5% of patients withdrew from the study. No direct, drug related serious adverse events were identified. 460 infants had a total of 541 hospitalizations for a spectrum of respiratory tract illnesses resulting in a hospitalization rate of 6.0%.The overall RSV positive hospitalization rate was 1.47% with no mortality. Living with siblings was significantly correlated with a shorter time to first RSV-positive hospitalization (B=0.615, df=1, p=0.046).Conclusions: The RSV hospitalization rate observed in the 2005-2010 RSV seasons was similar to that found in several published reports of infants receiving prophylaxis (range 1.3%-5.3%). ER -